Quick Facts
  • pin location icon
    Primary Location:
    MD Anderson Cancer Center
  • wavy circle icon with check mark inside
    Clinical Trials
    Thoracic Malignancies
  • magnifying glass with heart icon
    Medical Oncology
  • gender symbols interlocked icon
  • chat box with different language translations icon
  • certificate with a ribbon icon below
    Med School:
    Baylor College of Medicine

Get to Know Dr. Frank V. Fossella

Dr. Frank Fossella is a professor of medicine and internist within the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston.

He has served as the principal investigator for more than 50 clinical trials, most of which were aimed at finding a better, more effective treatment for patients with lung cancer, which is his specialty. He also treats patients with other thoracic cancers, including pleural mesothelioma.

Fossella graduated from the nearby Baylor College of Medicine after receiving his undergraduate degree from the Cornell University College of Arts and Sciences in New York. He also did his internal medicine residency and medical oncology fellowship at Baylor.

Contact Dr. Frank V. Fossella
Doctor Jacques Fontaine and Doctor Virginia Wolf
Find a Mesothelioma Specialist
Get specialized treatment from experienced mesothelioma doctors.

Specialties of Dr. Frank V. Fossella

  • Pleural mesothelioma
  • Lung cancer
  • Clinical research

Dr. Frank V. Fossella’s Experience and Medical Education

  • University of Texas MD Anderson Cancer Center
  • Baylor College of Medicine (M.D.)
  • Baylor College of Medicine Affiliated Hospitals (Residency and fellowship)

Awards and Certifications

  • America’s Top Doctors for Cancer, Castle Connolly (2016-2020)
  • America’s Top Doctors, Castle Connolly (2016-2020)
  • Top Doctor, Houston Chronicle (2016-2017)
  • America’s Top Doctors, Newsweek (2015)

Publications of Dr. Frank V. Fossella

  • Gjyshi, O. et al. (2020, October). Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology.
  • Hong, L. et al. (2020, September). Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit from Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology.
  • Cascone, T. et al. (2020, July). A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clinical Cancer Research.